Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

What's all that noise-Improving the hospital soundscape.

Oleksy AJ, Schlesinger JJ.

J Clin Monit Comput. 2018 Nov 2. doi: 10.1007/s10877-018-0215-3. [Epub ahead of print] Review.

PMID:
30390171
2.

Patient-Directed Music Therapy in the ICU.

Bamikole PO, Theriault BM, Caldwell SL, Schlesinger JJ.

Crit Care Med. 2018 Nov;46(11):e1085. doi: 10.1097/CCM.0000000000003365. No abstract available.

PMID:
30312244
3.

EMR implementation of default opioid prescription quantities.

Theriault BM, Burger CF, Schlesinger JJ.

J Gen Intern Med. 2018 Nov;33(11):1827. doi: 10.1007/s11606-018-4604-6. No abstract available.

PMID:
30054884
4.

Acoustic features of auditory medical alarms-An experimental study of alarm volume.

Schlesinger JJ, Baum Miller SH, Nash K, Bruce M, Ashmead D, Shotwell MS, Edworthy JR, Wallace MT, Weinger MB.

J Acoust Soc Am. 2018 Jun;143(6):3688. doi: 10.1121/1.5043396.

PMID:
29960450
5.

Integration of an Abbreviated ICU Cognitive Failure Questionnaire.

Theriault BM, Schlesinger JJ.

Crit Care Med. 2018 May;46(5):e479-e480. doi: 10.1097/CCM.0000000000003008. No abstract available.

PMID:
29652722
6.

Potential Impact of Medical Marijuana on Nonmedical Opioid Use.

Theriault BM, Schlesinger JJ.

Am J Psychiatry. 2018 Mar 1;175(3):284. doi: 10.1176/appi.ajp.2017.17101149. No abstract available.

PMID:
29490499
7.

Rethinking Clinical Workflow.

Schlesinger JJ, Burdick K, Baum S, Bellomy M, Mueller D, MacDonald A, Chern A, Chrouser K, Burger C.

Anesthesiol Clin. 2018 Mar;36(1):99-116. doi: 10.1016/j.anclin.2017.10.008. Review.

PMID:
29425602
8.

Use of 23.4% Saline in Symptomatic Vasospasm and Cushing's Triad to Prevent Herniation and Death: A Case Report.

Poe LM, Janda AM, Burger CF, Schlesinger JJ.

A A Case Rep. 2017 Nov 1;9(9):265-267. doi: 10.1213/XAA.0000000000000587.

PMID:
28691981
9.

ICU-related PTSD - A review of PTSD and the potential effects of collaborative songwriting therapy.

Noyes EM, Schlesinger JJ.

J Crit Care. 2017 Dec;42:78-84. doi: 10.1016/j.jcrc.2017.06.014. Epub 2017 Jun 23. Review. No abstract available.

PMID:
28688241
10.

Angioedema: Perioperative management.

Maynard AA, Burger CF, Schlesinger JJ.

SAGE Open Med Case Rep. 2017 Jun 8;5:2050313X17713912. doi: 10.1177/2050313X17713912. eCollection 2017.

11.

Classifying Alarms: Seeking Durability, Credibility, Consistency, and Simplicity.

Edworthy JR, Schlesinger JJ, McNeer RR, Kristensen MS, Bennett CL.

Biomed Instrum Technol. 2017 Feb;51(s2):50-57. doi: 10.2345/0899-8205-51.s2.50.

PMID:
28296464
12.

In Response.

Schlesinger JJ.

Anesth Analg. 2015 Sep;121(3):836. doi: 10.1213/ANE.0000000000000764. No abstract available.

PMID:
26287307
13.

Methylene Blue for Acute Septic Cardiomyopathy in a Burned Patient.

Schlesinger JJ, Burger CF.

J Burn Care Res. 2016 May-Jun;37(3):e287-91. doi: 10.1097/BCR.0000000000000237.

PMID:
25798807
14.

Anaesthesia, surgery, obstetrics, and emergency care in Guyana.

Vansell HJ, Schlesinger JJ, Harvey A, Rohde JP, Persaud S, McQueen KA.

J Epidemiol Glob Health. 2015 Mar;5(1):75-83. doi: 10.1016/j.jegh.2014.08.003. Epub 2014 Oct 7.

15.

Applications of a noninvasive respiratory volume monitor for critical care medicine.

Schlesinger JJ.

Respir Care. 2015 May;60(5):e97-100. doi: 10.4187/respcare.03744. Epub 2015 Jan 27.

16.

Cryoamputation as a temporizing measure in severe burn injury.

Pennington JD, Wall AE, Schlesinger JJ, Higdon KK, Weavind L.

J Burn Care Res. 2014 Jul-Aug;35(4):e273-5. doi: 10.1097/BCR.0000000000000063.

PMID:
24978024
17.

Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.

Chotiwan N, Roehrig JT, Schlesinger JJ, Blair CD, Huang CY.

Virology. 2014 May;456-457:238-46. doi: 10.1016/j.virol.2014.03.031. Epub 2014 Apr 18.

18.

Improving pulse oximetry pitch perception with multisensory perceptual training.

Schlesinger JJ, Stevenson RA, Shotwell MS, Wallace MT.

Anesth Analg. 2014 Jun;118(6):1249-53. doi: 10.1213/ANE.0000000000000222.

PMID:
24846194
19.

Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.

Burger CF, Schlesinger JJ.

Ann Pharmacother. 2014 Feb;48(2):286-91. doi: 10.1177/1060028013511060. Epub 2013 Nov 6.

PMID:
24259642
20.

Effects of divided attention and operating room noise on perception of pulse oximeter pitch changes: a laboratory study.

Stevenson RA, Schlesinger JJ, Wallace MT.

Anesthesiology. 2013 Feb;118(2):376-81. doi: 10.1097/ALN.0b013e31827d417b.

21.

A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD, Roehrig JT.

Antiviral Res. 2012 Apr;94(1):1-8. doi: 10.1016/j.antiviral.2012.02.001. Epub 2012 Feb 15.

22.

Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes.

Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, Liu S, Martinez-Sobrido L, Diamond MS, Schlesinger JJ, de Silva A, Sallusto F, Jin X.

Virology. 2011 Feb 5;410(1):240-7. doi: 10.1016/j.virol.2010.11.007. Epub 2010 Dec 4. Erratum in: Virology. 2011 May 10;413(2):320. Liu, Shengyo-ng [corrected to Liu, Shengyong]; Martnez-Sobrido, Luis [corrected to Martinez-Sobrido, Luis].

23.

A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.

Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ.

Vaccine. 2010 Nov 29;28(51):8085-94. doi: 10.1016/j.vaccine.2010.10.004. Epub 2010 Oct 16.

PMID:
20959154
24.

Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, Schlesinger JJ.

Virology. 2009 Nov 25;394(2):175-82. doi: 10.1016/j.virol.2009.09.024. Epub 2009 Oct 14.

25.

Primary human endothelial cells support direct but not antibody-dependent enhancement of dengue viral infection.

Arévalo MT, Simpson-Haidaris PJ, Kou Z, Schlesinger JJ, Jin X.

J Med Virol. 2009 Mar;81(3):519-28. doi: 10.1002/jmv.21408.

PMID:
19152413
26.

An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells.

Rodrigo WW, Alcena DC, Rose RC, Jin X, Schlesinger JJ.

Am J Trop Med Hyg. 2009 Jan;80(1):61-5.

PMID:
19141841
27.

Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2.

Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, Comach G, Rose RC, Jin X, Schlesinger JJ.

Clin Vaccine Immunol. 2009 Feb;16(2):285-7. doi: 10.1128/CVI.00363-08. Epub 2008 Nov 26. Erratum in: Clin Vaccine Immunol. 2013 Jun;20(6):954. Rodrigo, W W I S [corrected to Rodrigo, W W Shanaka I].

28.

Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells.

Sapinoro R, Volcy K, Rodrigo WW, Schlesinger JJ, Dewhurst S.

Virology. 2008 Apr 10;373(2):274-86. doi: 10.1016/j.virol.2007.12.013. Epub 2008 Jan 14.

29.

Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells.

Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, Jin X.

J Med Virol. 2008 Jan;80(1):134-46.

PMID:
18041019
30.

Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro.

Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, Coppage M, Jin X.

J Virol. 2007 Dec;81(24):13325-34. Epub 2007 Oct 10.

31.

Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS.

J Virol. 2007 Dec;81(23):12816-26. Epub 2007 Sep 19.

32.

Flavivirus nonstructural protein NS1: complementary surprises.

Schlesinger JJ.

Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18879-80. Epub 2006 Dec 4. No abstract available.

34.
35.
36.

Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes.

Ryman KD, Ledger TN, Weir RC, Schlesinger JJ, Barrett AD.

J Gen Virol. 1997 Jun;78 ( Pt 6):1353-6.

PMID:
9191929
37.

Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain.

Schlesinger JJ, Chapman S, Nestorowicz A, Rice CM, Ginocchio TE, Chambers TJ.

J Gen Virol. 1996 Jun;77 ( Pt 6):1277-85.

PMID:
8683217
39.

Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.

Eckels KH, Dubois DR, Summers PL, Schlesinger JJ, Shelly M, Cohen S, Zhang YM, Lai CJ, Kurane I, Rothman A, et al.

Am J Trop Med Hyg. 1994 Apr;50(4):472-8.

PMID:
8166355
40.
41.

Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.

Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, Van Regenmortel MH, et al.

Virology. 1992 Apr;187(2):480-91.

PMID:
1372140
42.

New approaches to flavivirus vaccine development.

Schlesinger JJ, Putnak JR, Eckels KH.

Biotechnology. 1992;20:289-307. Review. No abstract available.

PMID:
1318137
43.
44.

Attenuation of wild-type yellow fever virus by passage in HeLa cells.

Barrett AD, Monath TP, Cropp CB, Adkins JA, Ledger TN, Gould EA, Schlesinger JJ, Kinney RM, Trent DW.

J Gen Virol. 1990 Oct;71 ( Pt 10):2301-6.

PMID:
2230735
47.

Immunogenicity of a purified fragment of 17D yellow fever envelope protein.

Brandriss MW, Schlesinger JJ, Walsh EE.

J Infect Dis. 1990 Jun;161(6):1134-9.

PMID:
1693159
48.

Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody.

Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE.

J Gen Virol. 1990 Mar;71 ( Pt 3):593-9.

PMID:
2138210
49.

Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.

Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P.

J Gen Virol. 1989 Nov;70 ( Pt 11):2953-61.

PMID:
2479715
50.

Supplemental Content

Loading ...
Support Center